合成和抗菌评价含有四度氨基分子的新型万科米辛衍生物
Yongwei Jiang1, Weixin Lin2, Subei Tan3
1Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
ACS omega
|August 14, 2023
概括
具有四级基的新型万科米辛类似物对抗耐药细菌表现出强烈的活性. 一种特定的衍生品,QAV-a1,对MRSA的抗药效果明显高于万科米辛,并且具有有利的药理动力学特征.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 临床环境中抗生素耐药性的威胁日益增加.
- 当前抗生素的局限性,如针对耐药菌株的万科米辛.
- 需要新型抗微生物药物以提高疗效.
研究的目的:
- 设计和合成包含四级氨基基部分的新型万科米辛类似物.
- 评估这些类似物对临床隔离的耐药细菌的抗菌活性.
- 识别具有增强疗效和有利的药理动力学特性的化合物.
主要方法:
- 用四级基组合成万科米辛类似物的化学合成.
- 在体外对各种耐药细菌菌株进行抗菌活性测试.
- 对有前途的候选化合物的药理动力学分析,包括半衰期的确定.
主要成果:
- 几种合成的万科米辛类似物表现出显著的抗菌活性.
- 一种特定的三四级氨万科米辛 (QAV) 衍生物,QAV-a1,表现出最强烈的活性.
- QAV-a1对抗抗甲素耐药黄金葡萄球菌 (MRSA) 的有效性是万科米辛的4倍至32倍.
- 与万科米辛 (4.3 ± 1.9小时) 相比,QAV-a1的半衰期更长 (5.19 ± 0.10小时).
结论:
- 与四级氨基部分的万科米辛类似物代表了对抗耐药细菌的有希望的策略.
- QAV-a1是一种高效的万科米辛衍生物,对MRSA具有优越的活性和改善的药理动力学特性.
- 这些发现支持进一步开发QAV-a1和相关化合物,用于对抗耐药性感染的临床应用.
相关概念视频
Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
Antimicrobial Effectiveness
48
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
48
Antibiotic Selection
54.7K
Overview
54.7K


